Incyte Corp., of Wilmington, Del., reported fourth quarter 2018 product-related revenues of $468 million, including net revenues of $380 million for Jakafi (ruxolitinib), up 26 percent from the fourth quarter of 2017 and $19 million for Iclusig (ponatinib), down 2 percent from 2017.